

Jakenz

Tofacitinib 5mg, 10mg

PRESCRIBER *TREATMENT* INITIATION CHECKLIST

(for use when first starting patients
on Jakenz treatment)

This document is approved by The Executive
Directorate of Pharmacovigilance, at SFDA

Patient:

Date:

Treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Ulcerative Colitis (UC) and Juvenile Idiopathic Arthritis (JIA) patients with tofacitinib should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of these respective conditions.

In a randomised post authorisation safety study in patients with RA who were 50 years of age or older with at least one additional cardiovascular risk factor, an increased incidence of myocardial infarctions and an increased incidence of malignancies, particularly NMSC, lung cancer and lymphoma was observed with tofacitinib compared to TNF inhibitors.

Events of serious infections, venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), cardiovascular risk (excluding MI), MI, herpes zoster, tuberculosis (TB) and other opportunistic infections, malignancy (including lymphoma and lung cancer), all-cause mortality, gastrointestinal perforations, interstitial lung disease, and laboratory abnormalities have been reported in patients treated with tofacitinib in clinical studies.

Serious VTE events including PE, some of which were fatal, and DVT have been observed in patients taking tofacitinib. A dose-dependent increased risk for VTE was observed in clinical study with tofacitinib, compared to TNF inhibitors.

Tofacitinib should only be used if no suitable treatment alternatives are available in patients:

- 65 years of age and older;
- patients with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers);
- patients with malignancy risk factors (e.g. current malignancy or history of malignancy other than a successfully treated non-melanoma skin cancer)

Patients should be closely monitored for any signs and symptoms, and laboratory abnormalities, for early identification of these risks.

This treatment initiation checklist intends to remind you of the risks associated with the use of tofacitinib and the recommended tests before first administering tofacitinib.

Prior to administration of tofacitinib to patients, please check the following:

Does this patient have any evidence of hepatic impairment (Child-Pugh A, B or C)?

☐ Yes ☐ No

Note the following:

- Severe hepatic impairment (Child-Pugh C): Tofacitinib should not be used
- Moderate hepatic impairment (Child-Pugh B):
 - RA, PsA and AS: Tofacitinib dose should be reduced to 5 mg once daily
 - UC: Dose should be reduced to 5 mg once daily when the indicated dose in the presence of normal hepatic function is 5 mg twice daily. Dose should be reduced to 5 mg twice daily when the indicated dose in the presence of normal hepatic function is 10 mg twice daily
 - JIA: Tofacitinib dose should be reduced to 5 mg once daily or weight-based equivalent once daily when the indicated dose in the presence of normal hepatic function is 5 mg or weight-based equivalent twice daily
- Mild hepatic impairment (Child-Pugh A): No dose adjustment is required

Does this patient have any evidence of renal impairment (based on creatinine clearance)?

☐ Yes ☐ No

Note the following:

- Severe renal impairment (creatinine clearance <30 mL/min):
 - RA, PsA and AS: Tofacitinib dose should be reduced to 5 mg once daily
 - UC: Dose should be reduced to 5 mg once daily when the indicated dose in the presence of normal renal function is 5 mg twice daily. Dose should be reduced to 5 mg twice daily when the indicated dose in the presence of normal renal function is 10 mg twice daily. Patients with severe renal impairment should remain on a reduced dose even after haemodialysis
 - JIA: Tofacitinib dose should be reduced to 5 mg once daily or weight-based equivalent once daily when the indicated dose in the presence of normal renal function is 5 mg or weight-based equivalent twice daily
- Mild (creatinine clearance 50–80 mL/min) or moderate renal impairment (creatinine clearance 30–49 mL/min): No dose adjustment is required

Is this patient currently pregnant or does this patient intend to become pregnant?

☐ Yes ☐ No

Have you informed female patients that:

- Use of tofacitinib during pregnancy is contraindicated? ☐ Yes ☐ No
- Women of childbearing potential should use effective contraception during treatment with tofacitinib and for at least 4 weeks after the last dose? ☐ Yes ☐ No

Is this patient breastfeeding or does this patient intend to breastfeed?

☐ Yes ☐ No

- Have you informed female patients that use of tofacitinib during breastfeeding is contraindicated? ☐ Yes ☐ No

Is this patient currently taking any biologics or any potent immunosuppressants, in which case Tofacitinib should be avoided

☐ Yes ☐ No

Note the following:

- Tofacitinib should be avoided in combination with biologics such as TNF antagonists, interleukin (IL)-1R antagonists, IL-6R antagonists, anti-CD20 monoclonal antibodies, IL-17 antagonists, IL-12/IL-23 antagonists, anti-integrins, selective co-stimulation modulators and potent immunosuppressants such as azathioprine, cyclosporine, 6-mercaptopurine, and tacrolimus because of the possibility of increased immunosuppression and increased risk of infection

Is the patient over 65 years of age?

☐ Yes ☐ No

If Yes:

Have you considered alternative treatment considering the increased risk of serious infections, MI and malignancies and all cause mortality?

☐ Yes ☐ No

Note the following:

- In patients over 65 years of age, tofacitinib should only be used in these patients if no suitable treatment alternatives are available

Is the patient over 65 years of age, a current or past long-time smoker or have a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors?

☐ Yes ☐ No

If Yes:

Are there any suitable treatment alternatives available for the patient?

☐ Yes ☐ No

Note the following:

- Given the increased risk of Major Adverse Cardiovascular Events (including MI), tofacitinib should only be used in these patients if no suitable treatment alternatives are available

Have you discussed with the patient how to recognise symptoms of MI and to promptly seek medical attention if they experience these?

☐ Yes ☐ No

Note the following:

- The patient should be informed to seek medical attention if they develop sudden severe chest pain or tightness (that may spread to arms, jaw, neck and back), shortness of breath, cold sweat, light headedness or sudden dizziness

Is the patient over 65 years of age, a current or past long-time smoker or have other malignancy risk factors (e.g. current or history of malignancy other than a successfully treated non-melanoma skin cancer)?

☐ Yes ☐ No

If Yes:

Are there any suitable treatment alternatives available for the patient?

☐ Yes ☐ No

Note the following:

- Given the increased risk of malignancy, tofacitinib should only be used if no suitable treatment alternatives are available

Does the patient have any risk factors for VTE?

☐ Yes ☐ No

Note the following:

- Tofacitinib should be used with caution in patients with known risk factors for VTE, regardless of indication and dosage
- Refer to the prescriber brochure for the VTE risk factors

For patients with RA with known risk factors for VTE, consider testing D-dimer levels after approximately 12 months of treatment. If D-dimer test result is $\geq 2 \times$ ULN, confirm that clinical benefits outweigh risks prior to a decision on treatment continuation with tofacitinib

Have you discussed with the patient how to recognise symptoms of VTE and to promptly seek medical attention if they experience these?

☐ Yes ☐ No

Note the following:

- The patient should be informed to seek medical attention if they develop sudden shortness of breath or difficulty breathing, chest pain or pain in upper back, swelling of the leg or arm, leg pain or tenderness, or redness or discoloration in the leg or arm while taking Jakenz

Promptly evaluate patients with signs and symptoms of VTE and discontinue tofacitinib in patients with suspected VTE, regardless of dose or indication.

Does this patient have any active infections including localised infections?

☐ Yes ☐ No

Note the following:

- Tofacitinib should not be initiated in patients with active TB, serious infections, such as sepsis, or opportunistic infections
- The risks and benefits of treatment should be considered prior to initiating tofacitinib in patients:
 - with recurrent infections
 - who have been exposed to TB
 - with a history of a serious or an opportunistic infection
 - who have resided or travelled in areas of endemic TB or endemic mycoses
 - who have underlying conditions that may predispose them to infection (e.g., history of chronic lung disease)

Has this patient been evaluated and tested for latent or active TB?

☐ Yes ☐ No

Note the following:

- Patients should be evaluated and tested for latent or active TB prior to and per applicable guidelines during administration of tofacitinib
- Patients with latent TB should be treated with standard antimycobacterial therapy before administering tofacitinib
- Anti-TB therapy should be considered for patients with latent or active TB as per applicable guidelines

Have you informed patients that viral reactivation has been observed in patients taking tofacitinib?

☐ Yes ☐ No

Note the following:

- Patients treated with tofacitinib who are Japanese or Korean, or patients with long standing RA who have previously received two or more biological DMARDs, or patients with an ALC less than 1,000 cells/mm³, or patients treated with 10 mg twice daily may have an increased risk of herpes zoster

Does this patient have a history of diverticulitis?

☐ Yes ☐ No

Note the following:

- Tofacitinib should be used with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis, patients with concomitant use of corticosteroids and/or nonsteroidal anti-inflammatory drugs [NSAIDs])

Does the patient have elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST)?

☐ Yes ☐ No

Note the following:

- Caution should be exercised when considering initiation of tofacitinib treatment in patients with elevated ALT or AST
- Following initiation, routine monitoring of liver tests and prompt investigation of the causes of any observed liver enzyme elevations are recommended to identify potential cases of drug-induced liver injury

Have all the patient's immunisations been brought up to date in agreement with current immunisation guidelines?

☐ Yes ☐ No

Note the following:

- Prior to initiating tofacitinib it is recommended that all patients, particularly pJIA and jPsA patients be brought up to date with all immunisations in agreement with current immunisation guidelines. It is recommended that live vaccines not be given concurrently with tofacitinib. The decision to use live vaccines prior to treatment should take into account the pre-existing immunosuppression in a given patient
- Prophylactic zoster vaccination should be considered in accordance with vaccination guidelines. Particular consideration should be given to patients with longstanding rheumatoid arthritis who have received two or more prior biological DMARDs. If live zoster vaccine is administered, it should only be administered to patients with a known history of chickenpox or those that are seropositive for varicella zoster virus (VZV). If the history of chickenpox is considered doubtful or unreliable it is recommended to test for antibodies against VZV
- Vaccination with live vaccines should occur at least 2 weeks, but preferably 4 weeks, prior to initiation of tofacitinib or in accordance with current vaccination guidelines regarding immunomodulatory medicinal products such as tofacitinib

Discussion with your patients:

Have you discussed the overall benefits and risks of tofacitinib with your patient?

☐ Yes ☐ No

Have you given the patient alert card to your patient?

☐ Yes ☐ No

Have you discussed the use of the patient alert card with your patient?

☐ Yes ☐ No

Healthcare professionals are asked to report any suspected adverse reactions to the Saudi Food and Drug Authority (SFDA) via:



Website: <https://ade.sfda.gov.sa>

Email: npc.drug@sfda.gov.sa

Call center: 19999

Also, you can report to Sudair Pharma Company via:



Phone: +966-920001432 Ext. 107

Email: Pharmacovigilance@SudairPharma.com